BioCryst制药 BCRX 深 沪
等待开盘 10-30 09:30:00 美东时间
7.31
+0.070
+0.97%
华盛通- 最 高7.375
- 今 开7.18
- 成交量 507.43万股
- 最 低 7.17
- 昨 收 7.24
- 总市值 15.28亿
- 52周最高 11.31
- 市盈率 静 --
- 换手率 2.43%
- 52周最低 6.00
- 委 比 58.17%
- 总股本 2.09亿
- 历史最高 19.99
- 量 比 1.05
- 振 幅 2.83%
- 历史最低 1.08
- 每 手 1
- 风险率 1.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioCryst Pharmaceuticals To Present Four Abstracts From Second Interim Analysis of APeX-P Trial At Annual Scientific Meeting Of The American College Of Allergy, Asthma & Immunology In Orlando, Florida
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking
10-23 19:03
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
<p><p align="justify">BioCryst Pharmaceuticals will present four abstracts at the ACAAI meeting in November 2025, showcasing long-term prophylaxis data with ORLADEYO in pediatric HAE patients and psychosocial impact studies. ORLADEYO is the only oral therapy for HAE prevention in adults and adolescents, targeting plasma kallikrein. The study aims to evaluate safety and efficacy in younger patients. Key safety considerations include dosage adjustm...
10-23 11:00
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
TD Cowen Reinstates Buy on BioCryst Pharma, Announces $30 Price Target
TD Cowen analyst Stacy Ku reinstates BioCryst Pharma (NASDAQ:BCRX) with a Buy and announces $30 price target.
10-15 22:15
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
BioCryst to buy Astria Therapeutics for $13 per share
BioCryst Pharmaceuticals (NASDAQ:BCRX) has agreed to acquire biopharmaceutical firm Astria Therapeutics (NASDAQ:ATXS) for a mix of cash and stock representing an implied value of $13.00 per Astria sha...
10-14 19:20
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics for approximately $700 million in enterprise value, with the aim of adding Astria's Phase 3 HAE drug candidate, navenibart, to its portfolio. The deal is expected to solidify double-digit growth for BioCryst's HAE division over the next decade and maintain profitability. Navenibart is a long-acting, injectable therapy with a differentiated dosing schedule, addressing unmet needs i...
10-14 11:00
BioCryst Pharmaceuticals And Biocryst Ireland Entered Into A Trademark License Agreement
-SEC Filing
10-01 21:37
BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business
BuyCryst Pharmaceuticals completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million, with up to $14 million in future milestones. BioCryst will focus on U.S. sales while Neopharmed Gentili handles commercialization in Europe. The transaction boosts BioCryst's operating margin, simplifies operations, and enables debt repayment. ORLADEYO's commercial success is expected to continue globally.
10-01 11:00
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
BioCardia, Inc. announced positive results from its open-label CardiAMP Cell Therapy trial for patients with chronic myocardial ischemia and refractory angina. The minimally invasive therapy showed significant improvement, with patients experiencing an average 80-second increase in exercise tolerance and an 82% reduction in angina episodes at six months. These results outperform existing FDA-approved treatments like Ranolazine and EECP. CardiAMP ...
09-18 11:00
